Age
Item
1. 18 years and older;
boolean
C0001779 (UMLS CUI [1])
Prostatic Cancer, Castration-Resistant
Item
2. patients with crpc according to european association of urology diagnostic criteria ;
boolean
C3658266 (UMLS CUI [1])
Organ function | Bone Marrow function | Cardiac function | Liver function | Renal function
Item
3. vital organs functions including bone marrow, heart, liver, kidney are normal;
boolean
C0678852 (UMLS CUI [1])
C0005953 (UMLS CUI [2,1])
C0031843 (UMLS CUI [2,2])
C0232164 (UMLS CUI [3])
C0232741 (UMLS CUI [4])
C0232804 (UMLS CUI [5])
Specimen Complete Prostate carcinoma | Specimen Complete Hormone refractory prostate cancer | Biopsy | Surgical specimen | Biopsy Repeated Specimen | Transurethral Resection of Prostate Specimen | Neoplasm Metastasis Surgical specimen Palliative | Sample Deoxyribonucleic acid extraction | Quality Control Specimen | RNA Degradation Sample Absent | Absence DNA Sample | Amount Sample
Item
4. complete pathological specimens including newly diagnosed with prostate cancer and disease progress to crpc: ① biopsies or surgical specimens (tissue bank or wax block preserved specimens) at diagnosis ; ② re-biopsy specimens,transurethral prostatectomy (turp) specimens, metastases palliative surgical specimens (tissue bank or wax block preserved specimens) after progress to crpc; ③ amount sufficient sample for dna extraction and quality control by up to standard (a) sample type: none rna degradation and pollution-free dna samples; (b) the amount of the sample (single): ≥
boolean
C0370003 (UMLS CUI [1,1])
C0205197 (UMLS CUI [1,2])
C0600139 (UMLS CUI [1,3])
C0370003 (UMLS CUI [2,1])
C0205197 (UMLS CUI [2,2])
C1328504 (UMLS CUI [2,3])
C0005558 (UMLS CUI [3])
C1647891 (UMLS CUI [4])
C0005558 (UMLS CUI [5,1])
C0205341 (UMLS CUI [5,2])
C0370003 (UMLS CUI [5,3])
C0040771 (UMLS CUI [6,1])
C0370003 (UMLS CUI [6,2])
C0027627 (UMLS CUI [7,1])
C1647891 (UMLS CUI [7,2])
C1285530 (UMLS CUI [7,3])
C0370003 (UMLS CUI [8,1])
C3839098 (UMLS CUI [8,2])
C1561524 (UMLS CUI [9])
C1257756 (UMLS CUI [10,1])
C0370003 (UMLS CUI [10,2])
C0332197 (UMLS CUI [10,3])
C0332197 (UMLS CUI [11,1])
C0012854 (UMLS CUI [11,2])
C0370003 (UMLS CUI [11,3])
C1265611 (UMLS CUI [12,1])
C0370003 (UMLS CUI [12,2])
Sample Concentration measurement | Sample Purity
Item
250ng (using agilent liquid platform); (c) sample concentration: ≥ 50 ng / μl (using agilent liquid platform); (d) sample purity: od 260/280 = 1.8 ~ 2.0 );
boolean
C0370003 (UMLS CUI [1,1])
C1446561 (UMLS CUI [1,2])
C0370003 (UMLS CUI [2,1])
C1882508 (UMLS CUI [2,2])
Hematoxylin and eosin stain method | Immunohistochemistry | Sequencing of exon of gene
Item
5. then we perform following tests when patients meet the above criteria: ①histological analysis: hematoxylin-eosin(he) staining ②immunohistochemistry(ihc) staining ③ 48 carcinomas associated exon sequencing
boolean
C0523207 (UMLS CUI [1])
C0021044 (UMLS CUI [2])
C2733343 (UMLS CUI [3])
Treatment Group | docetaxel | Prednisone | PSA High | Gene Mutation Absent | Treatment Group | docetaxel | Prednisone | Drugs Targeted | PSA High | Gene Mutation | Treatment Group | Cisplatin | Etoposide | PSA low | Gene Mutation Absent
Item
6. after performing the above test, enter treatment group ① docetaxel & prednisone(dp) : with high psa and no gene mutation; ② dp + targeted drugs: with high psa and gene mutations; ③ cisplatin & etoposide(ep) : low psa and no gene mutation; ④ ep +
boolean
C0087111 (UMLS CUI [1,1])
C0441833 (UMLS CUI [1,2])
C0246415 (UMLS CUI [2])
C0032952 (UMLS CUI [3])
C0138741 (UMLS CUI [4,1])
C0205250 (UMLS CUI [4,2])
C0596611 (UMLS CUI [5,1])
C0332197 (UMLS CUI [5,2])
C0087111 (UMLS CUI [6,1])
C0441833 (UMLS CUI [6,2])
C0246415 (UMLS CUI [7])
C0032952 (UMLS CUI [8])
C0013227 (UMLS CUI [9,1])
C1521840 (UMLS CUI [9,2])
C0138741 (UMLS CUI [10,1])
C0205250 (UMLS CUI [10,2])
C0596611 (UMLS CUI [11])
C0087111 (UMLS CUI [12,1])
C0441833 (UMLS CUI [12,2])
C0008838 (UMLS CUI [13])
C0015133 (UMLS CUI [14])
C0138741 (UMLS CUI [15,1])
C0205251 (UMLS CUI [15,2])
C0596611 (UMLS CUI [16,1])
C0332197 (UMLS CUI [16,2])
Treatment Group | Etoposide | Drugs Targeted | PSA low | Gene Mutation
Item
targeted drug: low psa and gene mutations.
boolean
C0087111 (UMLS CUI [1,1])
C0441833 (UMLS CUI [1,2])
C0015133 (UMLS CUI [2])
C0013227 (UMLS CUI [3,1])
C1521840 (UMLS CUI [3,2])
C0138741 (UMLS CUI [4,1])
C0205251 (UMLS CUI [4,2])
C0596611 (UMLS CUI [5])
Peripheral blood Sample | Circulating Neoplastic Cells
Item
7. all patients enrolled in draw peripheral blood samples 7.5ml and detect circulating tumor cells (ctc) , monitoring efficacy.
boolean
C0229664 (UMLS CUI [1,1])
C0370003 (UMLS CUI [1,2])
C0027625 (UMLS CUI [2])
Protocol Compliance | Informed Consent
Item
8. willing and able to comply with the program during the study period. 9 before entering clinical trials to provide written informed consent form, and the patient has to know you can withdraw from the study at any time in the study, and without any loss.
boolean
C0525058 (UMLS CUI [1])
C0021430 (UMLS CUI [2])
Availability of Blood specimen | Availability of Tissue specimen | Life Expectancy | Karnofsky Performance Status | ECOG performance status | Informed Consent
Item
10. agrees to provide blood and tissue specimens. 11 expected survival of> 6 months 12.karnofsky performance status (kps)> 60; eastern cooperative oncology group(ecog) score 0-2 13 signed informed consent form
boolean
C0470187 (UMLS CUI [1,1])
C0178913 (UMLS CUI [1,2])
C0470187 (UMLS CUI [2,1])
C1292533 (UMLS CUI [2,2])
C0023671 (UMLS CUI [3])
C0206065 (UMLS CUI [4])
C1520224 (UMLS CUI [5])
C0021430 (UMLS CUI [6])
Cancer Other
Item
1. other cancers
boolean
C1707251 (UMLS CUI [1])
Impaired cognition | Mental handicap
Item
2. cognitive inability and mental abnormalities
boolean
C0338656 (UMLS CUI [1])
C1306341 (UMLS CUI [2])
Disease Serious | Condition Serious
Item
3. other serious disease or condition
boolean
C0012634 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0348080 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
Internal medicine Disease Severe Uncontrolled | Communicable Disease Severe Uncontrolled
Item
severe, uncontrolled internal medicine and infectious diseases
boolean
C0021782 (UMLS CUI [1,1])
C0012634 (UMLS CUI [1,2])
C0205082 (UMLS CUI [1,3])
C0205318 (UMLS CUI [1,4])
C0009450 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C0205318 (UMLS CUI [2,3])
Digestive System Disorder Severe Uncontrolled
Item
severe digestive disorder can not control
boolean
C0012242 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0205318 (UMLS CUI [1,3])
Electrolyte imbalance Severe
Item
severe electrolyte imbalance
boolean
C0342579 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
Disseminated Intravascular Coagulation
Item
active disseminated intravascular coagulation
boolean
C0012739 (UMLS CUI [1])
Organ Major Failure | Decompensated cardiac failure | Pulmonary failure Decompensated | Liver Failure Decompensated | Kidney Failure Decompensated
Item
major organ failure, such as decompensated heart, lung, liver, kidney failure
boolean
C0178784 (UMLS CUI [1,1])
C0205164 (UMLS CUI [1,2])
C0231174 (UMLS CUI [1,3])
C0581377 (UMLS CUI [2])
C0948755 (UMLS CUI [3,1])
C0205434 (UMLS CUI [3,2])
C0085605 (UMLS CUI [4,1])
C0205434 (UMLS CUI [4,2])
C0035078 (UMLS CUI [5,1])
C0205434 (UMLS CUI [5,2])
Peripheral Neuropathy Symptoms CTCAE Grades
Item
peripheral neuropathy symptoms, nci grade> ⅱ degree
boolean
C0031117 (UMLS CUI [1,1])
C1457887 (UMLS CUI [1,2])
C1516728 (UMLS CUI [1,3])
Intolerance Chemotherapy | Chemotherapy Refused
Item
4. can not tolerate chemotherapy or refuse chemotherapy
boolean
C0231199 (UMLS CUI [1,1])
C0392920 (UMLS CUI [1,2])
C0392920 (UMLS CUI [2,1])
C1705116 (UMLS CUI [2,2])
Investigational New Drugs | Study Subject Participation Status | Clinical Trial
Item
5. using the other test drug or participate other clinical trials
boolean
C0013230 (UMLS CUI [1])
C2348568 (UMLS CUI [2])
C0008976 (UMLS CUI [3])
Lacking Able to swallow Oral medication
Item
6. can not oral drugs
boolean
C0332268 (UMLS CUI [1,1])
C2712086 (UMLS CUI [1,2])
C0175795 (UMLS CUI [1,3])
Chemotherapy | Biological treatment | Cancer treatment | Treatment Interval
Item
7. receiving chemotherapy, biological therapy, or other anti-cancer medicine intervals less than 4 weeks
boolean
C0392920 (UMLS CUI [1])
C1531518 (UMLS CUI [2])
C0920425 (UMLS CUI [3])
C0087111 (UMLS CUI [4,1])
C1272706 (UMLS CUI [4,2])
Study Subject Participation Status Inappropriate | Compliance behavior Lacking
Item
8. researchers believe patients unsuitable (compliance, we should not follow-up)
boolean
C2348568 (UMLS CUI [1,1])
C1548788 (UMLS CUI [1,2])
C1321605 (UMLS CUI [2,1])
C0332268 (UMLS CUI [2,2])